Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside

Research output: Contribution to journal › Review › Research › peer-review

Standard

Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside. / Ashina, Messoud; Hoffmann, Jan; Ashina, Håkan; Hay, Debbie L.; Flores-Montanez, Yadira; Do, Thien Phu; De Icco, Roberto; Dodick, David W.

In: Mayo Clinic Proceedings, Vol. 99, No. 2, 2024, p. 285-299.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Ashina, M, Hoffmann, J, Ashina, H, Hay, DL, Flores-Montanez, Y, Do, TP, De Icco, R & Dodick, DW 2024, 'Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside', Mayo Clinic Proceedings, vol. 99, no. 2, pp. 285-299. https://doi.org/10.1016/j.mayocp.2023.07.003

APA

Ashina, M., Hoffmann, J., Ashina, H., Hay, D. L., Flores-Montanez, Y., Do, T. P., De Icco, R., & Dodick, D. W. (2024). Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside. Mayo Clinic Proceedings, 99(2), 285-299. https://doi.org/10.1016/j.mayocp.2023.07.003

Vancouver

Ashina M, Hoffmann J, Ashina H, Hay DL, Flores-Montanez Y, Do TP et al. Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside. Mayo Clinic Proceedings. 2024;99(2):285-299. https://doi.org/10.1016/j.mayocp.2023.07.003

Author

Ashina, Messoud ; Hoffmann, Jan ; Ashina, Håkan ; Hay, Debbie L. ; Flores-Montanez, Yadira ; Do, Thien Phu ; De Icco, Roberto ; Dodick, David W. / Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside. In: Mayo Clinic Proceedings. 2024 ; Vol. 99, No. 2. pp. 285-299.

Bibtex

@article{673cdf8b75bf4cb9a98b086b0a26e4ca,
title = "Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside",
abstract = "Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.",
author = "Messoud Ashina and Jan Hoffmann and H{\aa}kan Ashina and Hay, {Debbie L.} and Yadira Flores-Montanez and Do, {Thien Phu} and {De Icco}, Roberto and Dodick, {David W.}",
note = "Publisher Copyright: {\textcopyright} 2023 Mayo Foundation for Medical Education and Research",
year = "2024",
doi = "10.1016/j.mayocp.2023.07.003",
language = "English",
volume = "99",
pages = "285--299",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside

AU - Ashina, Messoud

AU - Hoffmann, Jan

AU - Ashina, Håkan

AU - Hay, Debbie L.

AU - Flores-Montanez, Yadira

AU - Do, Thien Phu

AU - De Icco, Roberto

AU - Dodick, David W.

N1 - Publisher Copyright: © 2023 Mayo Foundation for Medical Education and Research

PY - 2024

Y1 - 2024

N2 - Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.

AB - Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.

U2 - 10.1016/j.mayocp.2023.07.003

DO - 10.1016/j.mayocp.2023.07.003

M3 - Review

C2 - 38180396

AN - SCOPUS:85184278621

VL - 99

SP - 285

EP - 299

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -

ID: 382978472